{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:54:49Z","timestamp":1788382489746,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ymgmr.2022.100845","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T20:46:20Z","timestamp":1643748380000},"page":"100845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Timing is everything: Clinical courses of Hunter syndrome associated with age at initiation of therapy in a sibling pair"],"prefix":"10.1016","volume":"30","author":[{"given":"Nathan","family":"Grant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Bae","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Matthew","family":"Ellinwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ericka","family":"Okenfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce A.","family":"Mendelsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie E.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Braunlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Harmatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie B.","family":"Eisengart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2022.100845_bb0005","first-page":"e1228","volume":"124","author":"Muenzer","year":"2009","journal-title":"Multidisc. Manag. Hunter Syndr. Pediatr."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0010","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3421","article-title":"The mucopolysaccharidoses","volume":"8","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0015","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","article-title":"Mortality and cause of death in mucopolysaccharidosis type II\u2014a historical review based on data from the hunter outcome survey (HOS)","volume":"32","author":"Jones","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0020","first-page":"100549","article-title":"The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome","volume":"22","author":"Eisengart","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2017.08.009","article-title":"Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations\u2014neurological signs and symptoms","volume":"122","author":"Shapiro","year":"2017","journal-title":"Mol. Genet. Metabolism"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0030","article-title":"Sibling and family caregivers","volume":"362","author":"Grant","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0035","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1002\/ajmg.a.62460","article-title":"The experiences and support needs of siblings of people with mucopolysaccharidosis","volume":"185","author":"Grant","year":"2021","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0040","doi-asserted-by":"crossref","DOI":"10.12968\/bjon.2016.25.1.22","article-title":"Management of the behavioural manifestations of hunter syndrome","volume":"25","author":"Roberts","year":"2016","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0045","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ymgme.2014.12.299","article-title":"Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II","volume":"114","author":"Yund","year":"2015","journal-title":"Mol. Genet. Metabolism"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ymgmr.2016.03.005","article-title":"A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II","volume":"7","author":"Shapiro","year":"2016","journal-title":"Mol. Genet. Metab. Reports"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2019.07.016","article-title":"Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England","volume":"129","author":"Broomfield","year":"2020","journal-title":"Mol. Genet. Metabolism"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0060","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00431-012-1703-y","article-title":"Diagnosing hunter syndrome in pediatric practice: practical considerations and common pitfalls","volume":"171","author":"Burton","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","article-title":"Early initiation of enzyme replacement therapy for the mucopolysaccharidoses","volume":"111","author":"Muenzer","year":"2014","journal-title":"Mol. Genet. Metabolism"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0070","first-page":"320","article-title":"Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II","volume":"159","author":"Holt","year":"2011"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0075","doi-asserted-by":"crossref","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","article-title":"Natural progression of neurological disease in mucopolysaccharidosis type II","volume":"127","author":"Holt","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0080","series-title":"Nationwide Newborn Screening Program for Mucopolysaccharidoses in Taiwan and an Update of the \u201cGold Standard\u201d Criteria Required to Make a Confirmatory Diagnosis Diagnostics","first-page":"1583","volume":"11","author":"Chuang","year":"2021"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/ijns6030073","article-title":"Newborn screening for mucopolysaccharidosis type II in Illinois: an update","volume":"6","author":"Burton","year":"2020","journal-title":"Int. J. Neonat. Screening"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/ijns6040079","article-title":"Validation and implementation of a highly sensitive and efficient newborn screening assay for mucopolysaccharidosis type II","volume":"6","author":"Bilyeu","year":"2020","journal-title":"Int. J. Neonat. Screening"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0095","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/gim.2017.30","article-title":"Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review","volume":"19","author":"Bradley","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0100","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajmg.a.38551","article-title":"Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: data from the hunter outcome survey (HOS)","volume":"176","author":"Ficicioglu","year":"2018","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/jmg.19.6.401","article-title":"A clinical and genetic study of Hunter's syndrome. 1 heterogeneity","volume":"19","author":"Young","year":"1982","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0110","series-title":"Contemporary Intellectual Assessment: Theories, Tests, and Issues","first-page":"360","article-title":"The differential ability scales","author":"Elliott","year":"2018"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-021-02052-4","article-title":"Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)","volume":"16","author":"Muenzer","year":"2021","journal-title":"Orphanet J. Rare Diseases"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0120","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41436-020-0909-z","article-title":"Treatment of mucopolysaccharidosis type II (Hunter syndrome): a Delphi derived practice resource of the american College of Medical Genetics and Genomics (ACMG)","volume":"22","author":"McBride","year":"2020","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0125","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ymgme.2012.12.010","article-title":"Effects of idursulfase enzyme replacement therapy for mucopolysaccharidosis type II when started in early infancy: comparison in two siblings","volume":"108","author":"Tajima","year":"2013","journal-title":"Mol. Genet. Metabolism"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0130","first-page":"9","article-title":"Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: a case report","volume":"62","author":"Tomita","year":"2021","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0135","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1542\/peds.2009-1728","article-title":"Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up","volume":"125","author":"Gabrielli","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001380","article-title":"Replacing the enzyme \u03b1-l-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I","volume":"2","author":"Dierenfeld","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0150","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/gim.2016.223","article-title":"Cognitive outcomes and age of detection of severe mucopolysaccharidosis type 1","volume":"19","author":"Grosse","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0155","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1542\/peds.2012-0762","article-title":"Occurrence and family impact of elopement in children with autism spectrum disorders","volume":"130","author":"Anderson","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0160","first-page":"1","article-title":"Characteristics of unintentional drowning deaths in children with autism spectrum disorder","volume":"4","author":"Guan","year":"2017","journal-title":"Inj. Epidemiology"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-015-0356-0","article-title":"Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II","volume":"10","author":"Cho","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0170","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1093\/hmg\/ddq420","article-title":"Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy","volume":"19","author":"Polito","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0175","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ymgme.2013.03.005","article-title":"Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice - 1\u2013s2.0-S1096719213000942-main.Pdf","volume":"109","author":"Baldo","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001380","article-title":"Replacing the enzyme \u03b1-l-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I","volume":"2","author":"Dierenfeld","year":"2010","journal-title":"Sci. Transl. Medicine"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0185","doi-asserted-by":"crossref","first-page":"14777","DOI":"10.1073\/pnas.0506892102","article-title":"Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII","volume":"102","author":"Vogler","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0190","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.mehy.2014.01.029","article-title":"Lysosomal enzymes may cross the blood\u2013brain-barrier by pinocytosis: implications for enzyme replacement therapy","volume":"82","author":"Baldo","year":"2014","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0195","first-page":"153","article-title":"Are the extracellular pathways a conduit for the delivery of therapeutics to the brain?","author":"Banks","year":"2006","journal-title":"Front. Med. Chem."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0200","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.3390\/ijms22115490","article-title":"Gene therapy for mucopolysaccharidosis type II\u2014A review of the current possibilities","volume":"22","author":"Zapolnik","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0205","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/ijms21020500","article-title":"Genome editing for mucopolysaccharidoses","volume":"21","author":"Poletto","year":"2020","journal-title":"Int. J. Mol. Sciences"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0210","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00109-020-01935-6","article-title":"Lysosomal storage diseases: current therapies and future alternatives","volume":"98","author":"Leal","year":"2020","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0215","doi-asserted-by":"crossref","first-page":"7888","DOI":"10.3390\/ijms22157888","article-title":"Differences in MPS I and MPS II disease manifestations","volume":"22","author":"Hampe","year":"2021","journal-title":"Int. J. Mol. Sciences"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ymgme.2017.10.007","article-title":"Treatment of brain disease in the mucopolysaccharidoses","volume":"122","author":"Scarpa","year":"2017","journal-title":"Mol. Genet. Metabolism"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0225","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2021.03.002","article-title":"The natural history of neurocognition in MPS disorders: a review","volume":"133","author":"Shapiro","year":"2021","journal-title":"Mol. Genet. Metabolism"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0230","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ymgmr.2017.05.010","article-title":"Early hematopoietic stem cell transplantation in a patient with severe mucopolysaccharidosis II: a 7 years follow-up","volume":"12","author":"Barth","year":"2017","journal-title":"Mol. Genet. Metab. Reports"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0235","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jpeds.2012.07.052","article-title":"Enzyme replacement is associated with better cognitive outcomes after transplant in hurler syndrome","volume":"162","author":"Eisengart","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0240","first-page":"64","article-title":"Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome","volume":"13","author":"Eisengart","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-014-0129-1","article-title":"Clinical efficacy of enzyme replacement therapy in paediatric hunter patients, an independent study of 3.5 years","volume":"9","author":"Tomanin","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0250","first-page":"109","volume":"5","author":"Tan","year":"2013","journal-title":"Obstructive sleep apnea in children: a critical update Nature and science of sleep"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0255","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.patbio.2014.05.015","article-title":"Cognitive impairment in obstructive sleep apnea","volume":"62","author":"Gagnon","year":"2014","journal-title":"Pathol. Biol."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0260","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1651-2227.2007.00213.x","article-title":"Mucopolysaccharidosis type II: an update on mutation spectrum","volume":"96","author":"Froissart","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0265","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ymgme.2020.08.007","article-title":"Therapy development for the mucopolysaccharidoses: updated consensus recommendations for neuropsychological endpoints","volume":"131","author":"van der Lee","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0270","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40120-020-00226-z","article-title":"Parent experiences of sanfilippo syndrome impact and unmet treatment needs: a qualitative assessment","volume":"10","author":"Porter","year":"2021","journal-title":"Neurol. Therapy"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0275","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13023-019-1150-1","article-title":"Analysis of the caregiver burden associated with sanfilippo syndrome type B: panel recommendations based on qualitative and quantitative data","volume":"14","author":"Shapiro","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0280","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40273-013-0040-y","article-title":"Disutility of illness for caregivers and families: a systematic review of the literature","volume":"31","author":"Wittenberg","year":"2013","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0285","series-title":"The Patient\u2019s Voice in the Evaluation of Medicines","author":"Agency","year":"2013"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0290","first-page":"100630","article-title":"Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (Hunter syndrome): contribution of genotype to cognitive developmental course","volume":"24","author":"Seo","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0295","doi-asserted-by":"crossref","first-page":"10938","DOI":"10.3390\/ijms222010938","article-title":"Enzyme replacement therapy with pabinafusp alfa for neuronopathic mucopolysaccharidosis II: an integrated analysis of preclinical and clinical data","volume":"22","author":"Giugliani","year":"2021","journal-title":"Int. J. Mol. Sciences"},{"key":"10.1016\/j.ymgmr.2022.100845_bb0305","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13023-017-0583-7","article-title":"Early disease progression of hurler syndrome","volume":"12","author":"Kiely","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2022.100845_bb0310","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.40998","article-title":"Expert evaluation of strategies to modernize newborn screening in the United States","volume":"4","author":"Bailey","year":"2021","journal-title":"JAMA Netw. Open"}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426922000052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426922000052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:52:59Z","timestamp":1762001579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426922000052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":60,"alternative-id":["S2214426922000052"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100845","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1161868\/v1","asserted-by":"object"}]},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Timing is everything: Clinical courses of Hunter syndrome associated with age at initiation of therapy in a sibling pair","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100845","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100845"}}